ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Immunome Inc

Immunome Inc (IMNM)

14.22
-0.12
(-0.84%)
Closed May 25 4:00PM
14.22
0.00
(0.00%)
After Hours: 7:59PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
14.22
Bid
14.24
Ask
14.50
Volume
1,069,390
14.16 Day's Range 14.90
4.50 52 Week Range 30.958
Market Cap
Previous Close
14.34
Open
14.26
Last Trade
29
@
14.45
Last Trade Time
Financial Volume
$ 15,612,913
VWAP
14.5998
Average Volume (3m)
741,321
Shares Outstanding
42,729,847
Dividend Yield
-
PE Ratio
-5.70
Earnings Per Share (EPS)
-2.5
Revenue
14.02M
Net Profit
-106.81M

About Immunome Inc

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was $14.34. Over the last year, Immunome shares have traded in a share price range of $ 4.50 to $ 30.958.

Immunome currently has 42,729,847 shares outstanding. The market capitalization of Immunome is $608.47 million. Immunome has a price to earnings ratio (PE ratio) of -5.70.

IMNM Latest News

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of...

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief...

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Integration of AL102 and IM-1021 completed Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 IM-1021 and IM-3050 IND submissions expected in first quarter of 2025...

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and...

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief...

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.05-0.35038542396614.2715.4513.51591399114.03452935CS
4-0.06-0.42016806722714.2816.7913.51583300114.58904097CS
12-10.09-41.505553270324.3130.95813.51574132118.58417824CS
266.379.54545454557.9230.9586.9364883318.41817439CS
528.67156.2162162165.5530.9584.539936216.34934791CS
156-3.79-21.043864519718.0130.9582.0920992015.56298481CS
260-1.44-9.1954022988515.6663.782.0920035517.48767575CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

IMNM Discussion

View Posts
Monksdream Monksdream 2 months ago
IMNM 10Q due 3/22
👍️0
Monksdream Monksdream 3 months ago
IMNM new 52 week hi
👍️0
Monksdream Monksdream 4 months ago
IMNM new 52 week high
👍️0
OncoJock OncoJock 6 months ago
Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ
👍️0
OncoJock OncoJock 6 months ago
agree
👍️0
Laster Laster 8 months ago
Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.
👍️ 1
Laster Laster 8 months ago
I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.
👍️ 1
wiwineguy wiwineguy 11 months ago
Ha, sold in fall of 21 for $25.
👍️0
makinezmoney makinezmoney 11 months ago
$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa


Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies



GO $IMNM
👍️0
makinezmoney makinezmoney 11 months ago
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50


Offfffffffffff she goes.

Nice boomer



GO $IMNM
👍️0
Awl416 Awl416 11 months ago
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
👍️ 1
wiwineguy wiwineguy 3 years ago
you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu
👍️0
Harbor6460 Harbor6460 3 years ago
They cannot dilute on the bid. Only the ask
👍️0
Pedro2004 Pedro2004 3 years ago
Pulled down to under $20.00
👍️0
Pedro2004 Pedro2004 3 years ago
They pulled this down to under $21.00

I'm back-in at $21.00
👍️0
Major_Bankz Major_Bankz 3 years ago
$22.50 U worry too much, should be $25+ this afternoon IMO
👍️0
Pedro2004 Pedro2004 3 years ago
I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.
👍️0
Pedro2004 Pedro2004 3 years ago
This run could have broke $30 today. But the company killed-it.
👍️0
Major_Bankz Major_Bankz 3 years ago
yep, shorties portfolio will get destroyed here.
👍️0
Pedro2004 Pedro2004 3 years ago
The dilution is going to kill this run.
👍️0
Pedro2004 Pedro2004 3 years ago
Looks like the company is dumping shares on the bid.
👍️0
Major_Bankz Major_Bankz 3 years ago
I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO
👍️0
Major_Bankz Major_Bankz 3 years ago
Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO
👍️0
Major_Bankz Major_Bankz 3 years ago
Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.
👍️0
Major_Bankz Major_Bankz 3 years ago
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
👍️0